Nelson Dusetti , Research Director at the Cancer Research Center of Marseille (CRCM), Head of the Translational Research and Innovative Therapies Department, and Chair of TRANSLATE-IT CRCM, shared on LinkedIn:
“Precision oncology progresses through rigorous validation.
Congratulations to Andréa Witz, Alexandre Harlé, and all the co-authors on this important publication in Journal of Clinical Oncology (JCO Journals) reporting the genomic analyses of the PRODIGE-24/CCTG PA6 trial.
I am also pleased that our team contributed to this collaborative effort through the development and validation of transcriptomic biomarkers evaluated in this cohort.
This study reminds us that no single biomarker will be sufficient to personalize treatment in pancreatic cancer. The future lies in integrating genomics, transcriptomics and clinical data to better guide therapeutic decisions.
Studies like this illustrate the value of translational research and of close collaborations between clinicians, scientists and bioinformaticians.
This is how we will continue to move precision medicine closer to patients.”
Title: Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study
Authors: Andréa Witz, PharmD, Thierry Conroy, MD, Aurélien Lambert, MD, Julia Salleron, MS, Aboubacar Diallo, MS, Marie Husson, MS, Rémy Nicolle, PhD, et al., and Alexandre Harlé, PharmD
Read The Full Article:
